Phaseline

Targets › GCGR

GCGR (Glucagon receptor): drug programs, companies and trials

18 programs from 16 companies in 66 trials: 34 Phase 3, 18 Phase 1, 9 Phase 2, 5 Phase 4; Metabolic and endocrine, Cardiovascular, Gastroenterology; next expected readout Nov 2026.

G protein-coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. (UniProt, P47871)

Open in Phaseline: the race on GCGR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Joslin Diabetes CenterGlucagon
Glucagon receptor agonist
GCGRPhase 4HypoglycemiaJan 2027
Steno Diabetes Center CopenhagenGlucagon
Glucagon receptor agonist
GCGRPhase 4Type 1 Diabetes MellitusMay 2027
China National Center for Cardiovascular DiseasesMazdutide
Dual GLP-1/glucagon receptor agonist
GLP1R, GCGRPhase 4Obesity & OverweightDec 2027
West China HospitalMazdutide
GLP-1/GCG receptor dual agonist
GLP1R, GCGRPhase 4Metabolic Dysfunction-Associated SteatohepatitisFeb 2029
Eli LillyRetatrutide
Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist
GCGR, GLP1R, GIPRPhase 3Obesity; Type 2 Diabetes; Diabetes Mellitus, Type 2; Atherosclerotic Cardiovascular Disease (ASCVD) …Nov 2026
AstraZenecaElecoglipron
Dipeptidyl peptidase-4 (DPP-4) inhibitor
DPP4, GCK, GCGRPhase 3Obesity; Type 2 Diabetes Mellitus; Weight Management; Heart Failure With Preserved Ejection Fraction (HFpEF) …Nov 2026
Boehringer IngelheimSurvodutide
Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist
GLP1R, GCGRPhase 3Type 2 Diabetes; Metabolic Dysfunction Associated Steatohepatitis; Metabolic Dysfunction Associated Steatohepatitis (MASH); Healthy …Dec 2026
Eli LillyEloralintide (LY3841136)
GLP-1/GCG dual receptor agonist
GLP1R, GCGRPhase 3Overweight; Obesity; Sleep Apnea, Obstructive; Osteoarthritis …Dec 2026
AltimmunePemvidutide
GLP-1 and glucagon receptor dual agonist
GLP1R, GCGRPhase 3Metabolic Dysfunction-Associated Steatohepatitis (MASH); Alcohol-associated Liver DiseaseSep 2027
AstraZenecaAZD6234 (Lenbelintide)
Glucagon receptor agonist
GCGRPhase 3Obesity or OverweightAug 2028
RochePetrelintide
Dual GLP-1 and glucagon receptor agonist
GLP1R, GCGRPhase 3Obesity or OverweightOct 2028
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolMazdutide (IBI362)
Triple GLP-1/GIP/glucagon receptor agonist
GLP1R, GIPR, GCGRPhase 3Dementia, MildAug 2029
Hudson BiotechRetatrutide (LY3437943)
Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist
GCGR, GLP1R, GIPRPhase 2ObesityMar 2027
Hanmi Pharmaceutical CompanyHM15136
Glucagon analog
GCGRPhase 2Congenital HyperinsulinismMay 2027
City of Hope Medical CenterAllogenic Human Islet Cells
Intraportal infusion of insulin-producing pancreatic islet cells for metabolic restoration
INSULIN, GCGRPhase 2Type 1 Diabetes Mellitus; Diabetes Mellitus, Type 1Aug 2027
University of California, San DiegoVolagidemab
Glucagon receptor inhibitor
GCGRPhase 2Type 1 DiabetesJan 2028
AdventHealth Translational Research InstituteGlucagon
Glucagon receptor agonist
GCGRPhase 1ObesityDec 2026
The University of Texas Health Science Center at San AntonioVolagidemab (REMD-477)
Glucagon receptor inhibitor
GCGRPhase 1Non-DiabeticMay 2030

Conditions

Obesity (17) Obesity or Overweight (6) Type 2 Diabetes Mellitus (5) Overweight (4) Type 2 Diabetes (2) Healthy Participants (2) Hypoglycemia (2) Healthy (2) Type 1 Diabetes Mellitus (2) Type 1 Diabetes (2) Diabetes Mellitus, Type 2 (1) Atherosclerotic Cardiovascular Disease (ASCVD) (1)

Modalities

protein or peptide (10), small molecule (5), mixed (2)

Companies

Eli Lilly (2) AstraZeneca (2) Joslin Diabetes Center (1) Boehringer Ingelheim (1) Hanmi Pharmaceutical Company (1) City of Hope Medical Center (1) The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) University of California, San Diego (1) AdventHealth Translational Research Institute (1) Altimmune (1) Steno Diabetes Center Copenhagen (1) West China Hospital (1) Roche (1) China National Center for Cardiovascular Diseases (1) The University of Texas Health Science Center at San Antonio (1) Hudson Biotech (1)

Related targets

GLP1R (9) GIPR (3) DPP4 (1) GCK (1) INSULIN (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.